JAMA -- Search Result

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Welcome | My Account | E-mail Alerts | Access Rights | Sign In

Search Criteria:: Anywhere in Article: Chemotherapy

Results are shown in relevance ranked order. To rephrase your existing search criteria, press the "Back" button on your browser. [Help with Searching]

Try this search in JAMA & Archives Journals
or other journals
Alert me when:
New articles matching this search are published
Download Displayed Citations
to Citation Manager

Search Results

Results 1 to 10 (of 33 found)
[View Next 10 Results]

Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation
J. Milburn Jessup; Andrew Stewart; Frederick L. Greene; Bruce D. Minsky
JAMA. 2005;294:2703-2711.
ABSTRACT | FULL TEXT

View larger version (98K)

Figure 3. Percentage of Subgroups of Patients With Stage III Cancer Receiving Adjuvant Chemotherapy

A, The percentage of black patients with stage III colon cancer who received adjuvant chemotherapy was significantly lower than the percentage of whites in 1990-1991 and 1994-1995 (P<.001). This difference was no longer significant in 2001-2002. B, The percentage of women with stage III colon cancer who received adjuvant chemotherapy was significantly lower than the percentage of men in each period (P<.001). C, The percentage of patients 80 years or older with stage III colon cancer who received adjuvant chemotherapy was significantly lower than the percentage of patients younger than 60 years in each period (P<.01). P values were calculated by contingency table analysis with Bonferroni correction.

Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer
Philip A. Rowlings; Stephanie F. Williams; Karen H. Antman; Karen K. Fields; Joseph W. Fay; Elizabeth Reed; Corey J. Pelz; John P. Klein; Kathleen A. Sobocinski; M. John Kennedy; Cesar O. Freytes; Philip L. McCarthy, Jr; Roger H. Herzig; Edward A. Stadtmauer; Hillard M. Lazarus; Andrew L. Pecora; Jacob D. Bitran; Steven N. Wolff; Robert Peter Gale; James O. Armitage; William P. Vaughan; Gary Spitzer; Mary M. Horowitz
JAMA. 1999;282:1335-1343.
ABSTRACT | FULL TEXT

View larger version (37K)

Figure 2. Kaplan-Meier Estimates of Progression-Free Survival

A, By chemotherapy sensitivity pretransplantation, P<.001 overall. For complete response vs indeterminate/unknown, P = .10; complete response vs partial response, P<.001; partial response vs resistant, P = .02. B, In women with central nervous system or liver metastases, or any disease at 3 or more sites, P<.0001. For the curve indicating liver metastases, see footnote # of Table 2. C, For women receiving no adjuvant chemotherapy, receiving adjuvant chemotherapy with a disease-free interval (DFI) not longer than 18 months, and receiving adjuvant chemotherapy with a DFI longer than 18 months, P<.0001. D, For women with 0, 1, 2, 3, or more than 3 adverse prognostic factors (Table 2).

MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma
Aaron J. Schetter; Suet Yi Leung; Jane J. Sohn; Krista A. Zanetti; Elise D. Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L. W. Kwong; Gordon K. H. Au; Chang-Gong Liu; George A. Calin; Carlo M. Croce; Curtis C. Harris
JAMA. 2008;299:425-436.
ABSTRACT | FULL TEXT

View larger version (70K)

Figure 4. Combined Analysis of Maryland Test Cohort and Hong Kong Validation Cohort Examining Associations Between miR-21 Expression in Tumors and Receipt of Adjuvant Chemotherapy With Prognosis

This analysis includes all patients with TNM stage II or III cancer except those with mucinous adenocarcinoma or adenosquamous carcinoma histologies. A, For the 119 patients with stage II or III cancer, high miR-21 expression is associated with poor survival for those who received chemotherapy (P=.003). B, Among the 52 patients with stage II cancer, associations between high miR-21 expression and prognosis were not statistically significant in 14 (26.9%) of the individuals who received chemotherapy (P=.11). C, For all 67 patients with TNM stage III cancer, high miR-21 expression was significantly associated with poor survival among those who received chemotherapy (P=.007).

The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"
Sarah Elizabeth Harrington; Thomas J. Smith
JAMA. 2008;299:2667-2678.
ABSTRACT | FULL TEXT

View larger version

Table 1. Palliative Chemotherapy for Metastatic Disease for 4 Common Solid Tumors

Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial
Jaffer A. Ajani; Kathryn A. Winter; Leonard L. Gunderson; John Pedersen; Al B. Benson, III; Charles R. Thomas, Jr; Robert J. Mayer; Michael G. Haddock; Tyvin A. Rich; Christopher Willett
JAMA. 2008;299:1914-1921.
ABSTRACT | FULL TEXT

View larger version

Table 2. Acute Toxic Effects of Chemotherapy and Radiation

High-Dose Chemotherapy for Breast Cancer
Karen H. Antman; Daniel F. Heitjan; Gabriel N. Hortobagyi
JAMA. 1999;282:1701-1703.
EXTRACT | FULL TEXT

View larger version

Table 1. Randomized Trials of High-Dose Chemotherapy for the Treatment of Breast Cancer*

Prevalence of and Factors Associated With Persistent Pain Following Breast Cancer Surgery
Rune Gärtner; Maj-Britt Jensen; Jeanette Nielsen; Marianne Ewertz; Niels Kroman; Henrik Kehlet
JAMA. 2009;302:1985-1992.
ABSTRACT | FULL TEXT

View larger version

Table 2. Pain Adjusted for Age, Type of Surgery, Radiotherapy, and Chemotherapy Among 3253 Danish Women Having Surgery for Primary Breast Cancer

Association Between the Medicare Modernization Act of 2003 and Patient Wait Times and Travel Distance for Chemotherapy
Alisa M. Shea; Lesley H. Curtis; Bradley G. Hammill; Lisa D. DiMartino; Amy P. Abernethy; Kevin A. Schulman
JAMA. 2008;300:189-196.
ABSTRACT | FULL TEXT

View larger version

Table 2. Patient Wait Times and Travel Distance for Initial Chemotherapy Visit by Year and Treatment Setting

Medical Treatment of Advanced Testicular Cancer
Darren R. Feldman; George J. Bosl; Joel Sheinfeld; Robert J. Motzer
JAMA. 2008;299:672-684.
ABSTRACT | FULL TEXT

View larger version

Table 2. Randomized Trials of Different First-Line Chemotherapy Regimens in Patients With Good-Prognosis Metastatic Germ Cell Tumors

10.

Medical Treatment of Advanced Testicular Cancer
Darren R. Feldman; George J. Bosl; Joel Sheinfeld; Robert J. Motzer
JAMA. 2008;299:672-684.
ABSTRACT | FULL TEXT

View larger version

Table 3. Randomized Trials of First-Line Chemotherapy Regimens in Patients With Intermediate- or Poor-Prognosis Metastatic Germ Cell Tumors (GCTs)

[View Next 10 Results]

Search Criteria:: Anywhere in Article: Chemotherapy

| | |